Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New test may spot hidden throat reflux

NCT ID NCT01854970

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at 30 people with symptoms of laryngopharyngeal reflux (LPR), such as hoarseness or a lump in the throat, and compared their pH-impedance test results to healthy individuals. The goal was to see if this test can better detect LPR. Participants took the drug esomeprazole for 8 weeks to see how symptoms and test results changed.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
esomeprazole
What this could lead to
If successful, this could improve how doctors diagnose laryngopharyngeal reflux, leading to better treatment decisions.
What could go wrong
This is a small, completed study with only 30 participants, so results may not apply to everyone. It focuses on diagnosis, not a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Start date

May 2013

Finished

Jul 2015

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * age : 18 to 80 years old. * Written consent * Laryngopharyngeal symptoms (dysphonia, and/or globus and/or sensation, and/or pharyngeal pain, and/or cough) for 3 months at least. * No PPI for at least 15 days * Social security affiliation Exclusion Criteria: * Sinusitis or chronic rhinitis (in the previous year) * Laryngeal trauma, tracheotomy or pharyngolaryngeal surgery * pregnancy or absence of efficacy contraception * breast feeding * history of gastrointestinal pathology, diabetes, neurological condition * cardio-vascular history requiring the taking of Plavix * esomeprazole contraindication or intolerance

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Laryngopharyngeal reflux are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Laryngopharyngeal Reflux

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • CHU de Bordeaux

    Bordeaux, 33000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.